JNCI: Regular use of aspirin can prevent the risk of metastasis after diagnosis of colorectal cancer

Colorectal cancer is the third leading cause of cancer deaths in men and women in the United States, causing approximately 53,000 deaths last year .

Colorectal cancer is the third leading cause of cancer deaths in men and women in the United States .

Recently, Xidasainai Medical Center , a study led by cancer researchers showed that the diagnosis of colorectal cancer with colorectal cancer diagnosed in the diagnosis of colorectal cancer (CRC) before the long-term, regular use of aspirin at least 15 times / May reduce the risk of death from the disease by limiting the spread of cancerous tumors.

Although previous research data consistently show that low-dose aspirin can reduce the risk of colorectal cancer, the results of the research published in the peer-reviewed journal of the National Cancer Institute show that taking infant aspirin before the diagnosis of non-metastatic CRC has a higher rate of later metastasis.

Starting aspirin after the diagnosis of colorectal cancer does not have that strong benefit compared to taking it before the diagnosis.

Starting aspirin after the diagnosis of colorectal cancer does not have that strong benefit compared to taking it before the diagnosis.

prevention

Jane C.

How does aspirin work?

How does aspirin work? How does aspirin work?

Researchers believe that the different modes of action of aspirin and non-aspirin non-steroidal anti-inflammatory drugs will affect the survival rate of colorectal cancer.

Researchers believe that the different modes of action of aspirin and non-aspirin non-steroidal anti-inflammatory drugs will affect the survival rate of colorectal cancer.

Although non-aspirin non-steroidal anti-inflammatory drugs also inhibit platelet activation, they do not permanently inhibit platelet activation, which may be the reason why a strong association between their use and the reduction in the incidence of metastatic disease has not been found.

Participants who started taking aspirin regularly after diagnosis had better results than participants who did not take aspirin at all, but the benefits were not clear enough to be considered significant.

The use of aspirin before diagnosis and the probability of distant metastasis of colorectal cancer at the time of diagnosis

Figueiredo said that ongoing clinical trials are aimed at examining the impact of aspirin on mortality before and after the diagnosis of colorectal cancer.

"But taking aspirin also has potential harm.

References: Jane C Figueiredo, PhD, Eric J Jacobs, PhD, Christina C Newton, MSPH, Mark A Guinter, PhD, William G Cance, MD, Peter T Campbell, PhD, Associations of aspirin and non-aspirin non-steroidal anti -inflammatory drugs with colorectal cancer mortality after diagnosis,JNCI: Journal of the National Cancer Institute , 2021;, djab008,org/10.

Jane C Figueiredo, PhD, Eric J Jacobs, PhD, Christina C Newton, MSPH, Mark A Guinter, PhD, William G Cance, MD, Peter T Campbell, PhD, Associations of aspirin and non-aspirin non-steroidal anti-inflammatory drugs with colorectal cancer mortality after diagnosis,JNCI: Journal of the National Cancer Institute , 2021;, djab008,JNCI: Journal of the National Cancer Institute org/10.
1093/jnci/djab008">https://doi.
org/10.
1093/jnci/djab008 https://doi.
org/ 10.
1093/jnci/djab008 leave a message here